Centice releases study results of drug dispensing process risk levels
Centice, a company engaged in chemical verification of dispensed drug prescriptions and a manufacturer of PASS Rx system, has published findings related to the risk levels of the drug dispensing process from Pharmacy Quality Assurance and Rx Verification Study.
Research study preliminary findings showed that pharmacists can spend up to 50 hours correcting a single dispensing error or Quality Related Event (QRE).
Centice said that the error rates are extremely small as a percentage of total prescriptions filled, but when factored into dispensing prescriptions over time and at average volumes for pharmacies, errors that leave the pharmacy can impact pharmacy financial stability and customer retention.
Centice stated that a typical pharmacy dispensing 1,000 prescriptions a week can save as high as $23,000 per year by reducing QREs.
The study also revealed that, of those QRE’s that leave the pharmacy, strength dispensing errors occur more frequently than dosage or wrong drug errors.
Centice chairman of the board and CEO Scott Albert said that they commissioned this research to understand the risks the average pharmacy faces in the normal conduct of their business.
“Centice is about protecting pharmacists from the consequences of these risks and providing solutions that contribute to a best practice Quality Assurance program,” Albert said.
Centice PASS Rx pharmaceutical authentication sensor system is known to improve the verification process for dispensed medications, thereby improving quality and optimising workflow in the pharmacy.
Related Insight
Suppliers Directory
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
IT & Software Intelligence
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.